Status:
COMPLETED
The Effect of Growth Hormone Replacement on Liver Fat
Lead Sponsor:
Imperial College London
Collaborating Sponsors:
Novo Nordisk A/S
Conditions:
Growth Hormone, Recombinant
Fatty Liver
Eligibility:
All Genders
20-70 years
Brief Summary
We will examine a cohort of growth hormone deficient adults starting growth hormone (GH) replacement. The purpose of this study is to determine whether GH replacement reduces the fat content of the li...
Detailed Description
Adults with untreated growth hormone deficiency (GHD), a condition mostly due to pituitary disease, often show metabolic features similar to those described in the 'metabolic syndrome'. Growth hormone...
Eligibility Criteria
Inclusion
- 20-70 years of age
- Growth hormone deficiency, with (cohort 1) or without (cohort 2) planned growth hormone (GH) replacement
- clinically stable
Exclusion
- known hepatic disease
- Acromegaly
- Diabetes mellitus
- growth hormone replacement within the last 12 months
- cushing's disease, if not cured for at least 12 months
- any contraindication to MR studies as set out in the MR safety questionnaire
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00774579
Start Date
March 1 2008
End Date
October 1 2009
Last Update
July 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrinology & Metabolic Medicine, Imperial College
London, United Kingdom, W2 1NY